Robbins Geller Investigates Travere Therapeutics for Potential Securities Violations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Investigation Background: Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws by Travere Therapeutics, focusing on whether executives made materially false or misleading statements that could undermine investor confidence.
- Investor Losses: Travere investors who have suffered losses are encouraged to provide information to Robbins Geller, which may offer legal support and potential compensation for affected parties during the investigation.
- Company Overview: Travere Therapeutics specializes in developing therapies for rare kidney and metabolic diseases, and concerns regarding its business transparency and compliance could impact its market performance and investor trust.
- Law Firm Strength: Robbins Geller is a leading firm in securities fraud and shareholder litigation, ranked #1 by ISS for four out of the last five years, recovering over $2.5 billion for investors in 2024 alone, underscoring its significant influence in the industry.
Analyst Views on TVTX
Wall Street analysts forecast TVTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TVTX is 40.09 USD with a low forecast of 31.00 USD and a high forecast of 49.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 34.100
Low
31.00
Averages
40.09
High
49.00
Current: 34.100
Low
31.00
Averages
40.09
High
49.00
About TVTX
Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Company’s Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
